Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Lucid Diagnostics ( (LUCD) ) is now available.
Lucid Diagnostics Inc. is redeeming its 2023 Convertible Note by issuing new 2024 Convertible Notes to accredited investors, aiming to complete the process within the Optional Redemption Notice Period. These new notes offer a 12% interest rate, a five-year maturity, and conversion options into company stock. Investors are drawn by the secured nature of the notes and the potential for stock conversion, while Lucid ensures the transaction remains exempt from public offering regulations.
See more insights into LUCD stock on TipRanks’ Stock Analysis page.
